A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS)

NCT04079296 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

43

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myeloid Leukemia (AML)
Myelodysplastic Syndrome

Interventions

BIOLOGICAL: ASP7517

Sponsor

Astellas Pharma Global Development, Inc.